Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.
Xilio Therapeutics (Nasdaq: XLO), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie immuno-oncologiche attivate da tumori, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Mondiale sulla Salute di Morgan Stanley. Il presidente e CEO dell'azienda, René Russo, Pharm.D., parteciperà a un colloquio informale il 4 settembre 2024, alle 7:00 EDT.
Investitori e parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web di Xilio. Il webcast rimarrà disponibile per 30 giorni dopo l'evento, offrendo un'opportunità a chi non può partecipare dal vivo di aggiornarsi sugli sviluppi e le strategie più recenti dell'azienda nel campo del trattamento del cancro.
Xilio Therapeutics (Nasdaq: XLO), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias de inmuno-oncología activadas por tumores, ha anunciado su participación en la 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley. El presidente y CEO de la compañía, René Russo, Pharm.D., participará en una charla informal el 4 de septiembre de 2024, a las 7:00 am EDT.
Los inversores y las partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección 'Eventos y Presentaciones' del sitio web de Xilio. El webcast estará disponible durante 30 días después del evento, proporcionando una oportunidad para aquellos que no pueden asistir en vivo de ponerse al día con los últimos desarrollos y estrategias de la empresa en el campo del tratamiento del cáncer.
Xilio Therapeutics (Nasdaq: XLO)는 종양 활성화 면역 항암 요법 개발에 중점을 둔 임상 단계의 생명공학 회사로서 모건 스탠리 제22회 세계 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 René Russo, Pharm.D.는 2024년 9월 4일 오전 7시 EDT에 진행되는 파이어사이드 채팅에 참여할 예정입니다.
투자자와 관련 당사자는 Xilio 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다. 웹캐스트는 행사 후 30일 동안 이용 가능하여, 실시간으로 참석할 수 없는 이들이 최신 개발 사항 및 암 치료 분야에서의 전략을 알아볼 수 있는 기회를 제공합니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies d'immuno-oncologie activées par les tumeurs, a annoncé sa participation à la 22e Conférence Annuelle Mondiale de la Santé de Morgan Stanley. Le président et PDG de l'entreprise, René Russo, Pharm.D., participera à un échange informel le 4 septembre 2024 à 7h00 EDT.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation par le biais de la section 'Événements et présentations' sur le site web de Xilio. Le webcast restera disponible pendant 30 jours après l'événement, offrant ainsi une occasion à ceux qui ne peuvent pas assister en direct de se mettre à jour sur les derniers développements et stratégies de l’entreprise dans le domaine du traitement du cancer.
Xilio Therapeutics (Nasdaq: XLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von tumoraktivierten Immunonkologie-Therapien konzentriert, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley angekündigt. Der Präsident und CEO des Unternehmens, René Russo, Pharm.D., wird am 4. September 2024 um 7:00 Uhr EDT an einem Fireside-Chat teilnehmen.
Investoren und interessierte Parteien können über den Bereich 'Events & Präsentationen' auf Xilios Website auf ein Live-Webcast der Präsentation zugreifen. Der Webcast wird 30 Tage nach der Veranstaltung verfügbar bleiben und bietet somit Gelegenheit für diejenigen, die nicht live teilnehmen können, die neuesten Entwicklungen und Strategien des Unternehmens im Bereich der Krebsbehandlung nachzuholen.
- None.
- None.
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:00 am EDT.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
When is Xilio Therapeutics (XLO) presenting at the Morgan Stanley Healthcare Conference?
Who will be representing Xilio Therapeutics (XLO) at the Morgan Stanley conference?
How can I watch Xilio Therapeutics' (XLO) presentation at the Morgan Stanley conference?
How long will the replay of Xilio Therapeutics' (XLO) Morgan Stanley conference presentation be available?
What is the focus of Xilio Therapeutics' (XLO) research and development?
